VISEN Pharmaceuticals (HK:2561)
:2561
Want to see HK:2561 full AI Analyst Report?
2561 Stock Chart & Stats
HK$33.68
--
Market closed
HK$33.68
--
Day’s Range― - ―
52-Week RangeHK$19.16 - HK$52.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)37.57K
Market Cap
HK$2.21B
Enterprise ValueHK$1.39B
Total Cash (Recent Filing)HK$805.91M
Total Debt (Recent Filing)HK$1.20M
Price to Earnings (P/E)―
Beta1.06
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding113,926,865
10 Day Avg. Volume36,930
30 Day Avg. Volume37,566
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)4.01
Price to Sales (P/S)19001.90
P/FCF Ratio-6.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet: Low-to-moderate LeverageModest leverage provides durable financial flexibility despite operating losses, supporting continued R&D and operations without immediate refinancing pressure. Even with a 2025 debt step-up, a relatively strong balance sheet reduces near-term default risk and preserves strategic options over the next 2–6 months.
Positive Gross Profit In 2024–2025Sustained positive gross profit indicates underlying unit economics and product-level margin potential. This creates a structural pathway to profitability if operating expenses are controlled or revenue scales, making gross margin a durable foundation for future margin recovery once top-line performance stabilizes.
Industry Focus: Specialty & Generic PharmaceuticalsExposure to specialty and generic pharmaceuticals aligns the company with secular demand drivers—aging populations and recurring demand for medicines. Structural industry dynamics can support steady long-term revenue opportunities and partnership/licensing paths even as near-term commercial execution remains challenging.
Bears Say
Persistent Large Operating LossesContinued large net losses erode equity and limit internal reinvestment capacity, making the business dependent on external funding. Over a 2–6 month horizon this undermines strategic flexibility, raises dilution or refinancing risk, and constrains the firm’s ability to execute long-term development and commercialization plans.
Consistently Negative Operating And Free Cash FlowPersistent negative OCF and FCF indicate structural cash burn, forcing reliance on external capital to sustain operations and trials. This creates lasting financing risk, potential dilution, and vulnerability to tighter credit markets, constraining investment and growth over the medium term.
Sharp Revenue Decline And Weak Operating LeverageA material revenue decline undermines scaling benefits and lengthens the path to breakeven; weak operating leverage means fixed costs outpace revenue, raising the likelihood that additional cuts or financing will be needed. Structurally, declining sales reduce optionality for commercial expansion and margin recovery.
VISEN Pharmaceuticals News
2561 FAQ
What was VISEN Pharmaceuticals’s price range in the past 12 months?
VISEN Pharmaceuticals lowest stock price was HK$19.16 and its highest was HK$52.90 in the past 12 months.
What is VISEN Pharmaceuticals’s market cap?
VISEN Pharmaceuticals’s market cap is HK$2.21B.
When is VISEN Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were VISEN Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is VISEN Pharmaceuticals overvalued?
According to Wall Street analysts VISEN Pharmaceuticals’s price is currently Overvalued.
Does VISEN Pharmaceuticals pay dividends?
VISEN Pharmaceuticals does not currently pay dividends.
What is VISEN Pharmaceuticals’s EPS estimate?
VISEN Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VISEN Pharmaceuticals have?
VISEN Pharmaceuticals has 113,926,865 shares outstanding.
What happened to VISEN Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VISEN Pharmaceuticals?
Currently, no hedge funds are holding shares in HK:2561
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
VISEN Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
VISEN Pharmaceuticals
VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
Technical Analysis
HUTCHMED (China)
―
Hua Medicine
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
CanSino Biologics, Inc. Class H
―